Atossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Atossa Therapeutics (NASDAQ:ATOS) announced its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.01, Zacks reports.

Atossa Therapeutics Stock Down 0.2 %

Shares of ATOS traded down $0.00 on Tuesday, reaching $0.75. The stock had a trading volume of 71,899 shares, compared to its average volume of 1,017,699. The firm has a 50-day moving average of $0.80 and a 200 day moving average of $1.12. The firm has a market capitalization of $93.97 million, a PE ratio of -3.40 and a beta of 1.20. Atossa Therapeutics has a twelve month low of $0.66 and a twelve month high of $2.31.

Institutional Trading of Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE raised its holdings in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after acquiring an additional 37,809 shares during the quarter. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 12.74% of the company’s stock.

Wall Street Analyst Weigh In

ATOS has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Atossa Therapeutics in a research note on Wednesday, March 12th. Ascendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research report on Monday, December 9th.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.